Abstract
To demonstrate the economic advantages of using venetoclax (plus obinutuzumab [VenO] or rituximab [VenR]) vs acalabrutinib monotherapy (Acala) in the first line (1L) and relapse or refractory (R/R) chronic lymphocytic leukemia (CLL) treatment under the Brazilian public healthcare system (SUS).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
